Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study
Open Access
- 31 December 2000
- journal article
- clinical trial
- Published by Wiley in Otolaryngology -- Head and Neck Surgery
- Vol. 123 (6), 669-676
- https://doi.org/10.1067/mhn.2000.110960
Abstract
OBJECTIVE: The object of this clinical experience was to evaluate the correlation between pericranial botulinum toxin type A (BOTOX, Allergan Corp, Irvine, CA) administration and alleviation of migraine headache symptoms. STUDY DESIGN AND SETTING: A nonrandomized, open-label study was performed at 4 different test sites. The subjects consisted of 106 patients, predominantly female, who either (1) initially sought BOTOX treatment for hyperfunctional facial lines or other dystonias with concomitant headache disorders, or (2) were candidates for BOTOX treatment specifically for headaches. Headaches were classified as true migraine, possible migraine, or nonmi-graine, based on baseline headache characteristics and International Headache Society criteria. BOTOX was injected into the glabellar, temporal, frontal, and/or suboccipital regions of the head and neck. Main outcome measures were determined by severity and duration of response. The degrees of response were classified as: (1) complete (symptom elimination), (2) partial (≥50% reduction in headache frequency or severity), and (3) no response [neither (1) nor (2)]. Duration of response was measured in months for the prophylactic group. RESULTS: Among 77 true migraine subjects treated prophylactically, 51% (95% confidence interval, 39% to 62%) reported complete response with a mean (SD) response duration of 4.1 (2.6) months; 38% reported partial response with a mean (SD) response duration of 2.7 (1.2) months. Overall improvement was independent of baseline headache characteristics. Seventy percent (95% confidence interval, 35% to 93%) of 10 true migraine patients treated acutely reported complete response with improvement 1 to 2 hours after treatment. No adverse effects were reported. CONCLUSIONS: BOTOX was found to be a safe and effective therapy for both acute and prophylactic treatment of migraine headaches. Further research is needed to explore and develop the complete potential for the neuroinhibitory effects of botulinum toxin.Keywords
This publication has 17 references indexed in Scilit:
- Cytokines and soluble IL‐4 in patients with acute optic neuritis and multiple sclerosisEuropean Journal of Neurology, 1997
- Rhinorrhea is decreased in dogs after nasal application of botulinum toxinOtolaryngology -- Head and Neck Surgery, 1995
- Pathophysiology of migraine and tension-type headacheCurrent Opinion in Neurology, 1994
- Status epilepticus and antiepileptic medication levelsNeurology, 1994
- Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputsPain, 1991
- Correlation between essential tremor and migraine headache.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- High-frequency stimulation of the facial nerve results in local cortical release of vasoactive intestinal polypeptide in the anesthetised catNeuroscience Letters, 1990
- Extracranial vasodilatation mediated by vasoactive intestinal polypeptide (VIP)Brain Research, 1985
- The neurobiology of vascular head painAnnals of Neurology, 1984
- Psychophysiology of recurrent headache: Methodological issues and new empirical findingsBehavior Therapy, 1982